In the next sections we discuss how changes in the composition of the microbiota in IBD and metabolic disease contribute to BA dysregulation and how alterations in FXR and TGR5 activation might play a role in disease pathogenesis. This evidence concerns the gene NR1H4 and Other metabolic disease.